AstraZeneca’s IMFINZI Combination Cuts Bladder Cancer Recurrence Risk 49%
Positive Phase III VOLGA trial results showed perioperative IMFINZI (durvalumab) plus neoadjuvant enfortumab vedotin reduced recurrence risk by 49% and risk of death by 42%.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.